Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Healthcare Biotechnology
Hemostemix Inc. is a Canada-based autologous stem cell therapy company. The Company has developed, patented, and is scaling a patient’s blood-based stem cell therapeutics platform, which includes angiogenic cell precursors, neuronal cell precursors and cardiomyocyte cell precursors. The Company holds 87 patents on the derivation of three stem cell lineages from the patient’s blood, including... see more

Recent & Breaking News (TSXV:HEM)

Hemostemix Closes $762,400 of The Unit Private Placement

Newsfile March 21, 2023

Hemostemix Unit Offering Repriced

Newsfile March 8, 2023

Hemostemix (TSXV:HEM) offering US$17.5M in convertible debentures for therapy program

Caroline Egan  March 7, 2023

Hemostemix Offers up to 500 6% Convertible Debentures, Convertible into an ACP-01 Therapeutic Production Slot that is Subject to Compassionate Exemption from Regulatory Approval

Newsfile March 7, 2023

Hemostemix Announces Unit Private Placement

Newsfile February 1, 2023

The Force Family Office Engaged by Hemostemix

Newsfile January 31, 2023

Hemostemix' "Your Fountain of Youth" Trademark Granted by Switzerland

Newsfile January 30, 2023

Hemostemix' "Your Fountain of Youth" Trademark Granted by Japan Patent Office

Newsfile January 26, 2023

Hemostemix Wins Arbitration Decision

Newsfile January 24, 2023

Hemostemix Hiring 4 New Biotechnologists in Montreal and Appling for Grants to Fund Up To 75% of 5-Year Costs

Newsfile January 23, 2023

IIROC Trading Resumption - HEM

Canada NewsWire January 19, 2023

Hemostemix Announces Letter of Commitment, Non-Dilutive Funding Structure and $250,000 of Funding by the McGill University Health Centre Foundation

Newsfile January 19, 2023

IIROC Trading Halt - HEM

Canada NewsWire January 19, 2023

Hemostemix Issued 'Your Fountain of Youth' Trademark by Cyprus

Newsfile December 8, 2022

Hemostemix Thanks Neim Malo, Beefstro's Founder, for His ACP-01 Testimonial Interview

Newsfile November 30, 2022

Hemostemix Thanks Six-Time Grammy Award Winner, Howie Lindeman, for his ACP-01 Testimonial Interview

Newsfile November 17, 2022

Hemostemix (TSXV:HEM) advances production automation

Jonathon Brown November 15, 2022

Hemostemix Announces Advancements in Its Automation of Production

Newsfile November 15, 2022

Hemostemix Announces Dr. Giannetti and Dr. Cecere as Co-Lead Medical Consultants, Cardiovascular Clinical Trials

Newsfile October 26, 2022

Hemostemix Announces Presentation to the Emerging Growth Conference

Newsfile October 25, 2022